Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675765 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
A Phase 1 study, sponsored by Aduro Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01675765: Completed Phase 1 study, sponsored by Aduro Biotech.
NCT01675765 is a Phase 1 study that has completed, run by Aduro Biotech. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01675765, a Phase 1 study, has completed, sponsored by Aduro Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against the tumor-associated antigen mesothelin, which has been shown to be present at higher levels on certain tumor cells (such as mesothelioma) than on normal cells. Pemetrexed and cisplatin are the standard chemotherapy regimen to treat malignant pleural mesothelioma. This trial will evaluate whether giving CRS-207 cancer vaccine with chemotherapy will induce anti-tumor immune responses and/or objective tumor response.
Interventions
- BIOLOGICAL Immunotherapy plus chemotherapy
- BIOLOGICAL Immunotherapy with cyclophosphamide plus chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-09-03 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675765
The ClinicalTrials.gov registry entry for NCT01675765 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immunotherapy plus chemotherapy is the first listed.
NCT01675765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675765 about?
NCT01675765 is a clinical study titled "Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma". This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has...
What is the current status of trial NCT01675765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2014-09-03. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT01675765?
The interventions under investigation include: Immunotherapy plus chemotherapy (BIOLOGICAL), Immunotherapy with cyclophosphamide plus chemotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01675765?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.